• Go to navigation
  • Go to content
ProstateLine

Astrazeneca Worldwide

  • AstraZeneca Websites
Astrazeneca.com

Main navigation

  • Home
  • News
  • Prostate cancer
  • AstraZeneca products
  • Treatment guidelines
  • Expert views
  • Pubmed
  • Patient support
  • Congress calendar
  • Congress reports
  • Glossary
  • Register for extra features
  • Links
  • Sitemap

You are here

  • Home
  • AstraZeneca products

AstraZeneca is one of the world's major research-based pharmaceutical companies. AstraZeneca aims to be the first with new ideas and innovations in all areas of its activity.

It has a well-established reputation for researching and developing new drugs. This is backed by a strong research base, with some 12,000 employees dedicated to R+D at 17 research centres in 8 countries. R+D investment totals over $5 billion.

The company first became involved in cancer research in the 1960’s and has developed new drugs for the treatment of cancer.

For information about our products used in prostate cancer please see below:

CASODEX (bicalutamide) 50mgInternational Prescribing Information
CASODEX (bicalutamide) 150mgInternational Prescribing Information
ZOLADEX (goserelin) 10.8mgInternational Prescribing Information
ZOLADEX (goserelin) 3.6mgInternational Prescribing Information

 



Not signed in

Please log in or register to access the site



  • Register
  • Forgotten password?

Information

This is an AstraZeneca International website for healthcare professionals and is not intended for the following audiences who should use the links below. 

  • US Patients
  • US HCPs
  • UK Patients
  • UK HCPs
  • Patients Other

Unsubscribe

Unsubscribe

Contact

Contact Us

PubMed

  • Access PubMed

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2010